About: Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
Creator	Mojoli, Francesco Bruno, Raffaele Colaneri, Marta Zuccaro, Valentina Bogliolo, Laura Brandolino, Fabio Matteo, San Montecucco, Carlomaurizio Sacchi, Paolo Valsecchi, Pietro Force, Pavia Giusti, Maria Irccs, Covid
source	Medline; PMC
abstract	Objective: This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. Design: Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo COvid19 REgistry (SMACORE). A retrospective analysis of patients treated with TCZ matched using propensity score to patients treated with Standard Of Care (SOC) was conducted. Setting: The study was conducted at IRCCS Policlinico San Matteo Hospital, Pavia, Italy, from March 14, 2020 to March 27, 2020. Participants: Patients with a confirmed diagnosis of COVID-19 hospitalized in our institution at the time of TCZ availability. Interventions: TCZ was administered to 21 patients. The first administration was 8 mg/kg (up to a maximum 800 mg per dose) of Tocilizumab intravenously, repeated after 12 h if no side effects were reported after the first dose. Main Outcomes and Measures: ICU admission and 7-day mortality rate. Secondary outcomes included clinical and laboratory data. Results: There were 112 patients evaluated (82 were male and 30 were female, with a median age of 63.55 years). Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin). No adverse event was detected following TCZ administration. This study found that treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Conclusions: TCZ administration did not reduce ICU admission or mortality rate in a cohort of 21 patients. Additional data are needed to understand the effect(s) of TCZ in treating patients diagnosed with COVID-19.
has issue date	2020-05-09(xsd:dateTime)
bibo:doi	10.3390/microorganisms8050695
bibo:pmid	32397399
has license	cc-by
sha1sum (hex)	011911a1a77bf499259df213356cf8b097a69eff
schema:url	https://doi.org/10.3390/microorganisms8050695
resource representing a document's title	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
has PubMed Central identifier	PMC7285503
has PubMed identifier	32397399
schema:publication	Microorganisms
resource representing a document's body	covid:011911a1a77bf499259df213356cf8b097a69eff#body_text
is schema:about of	named entity 'TREATMENT' named entity 'RESULTS' named entity 'STUDY' named entity 'TIME' named entity 'FEMALE' named entity 'OBJECTIVE' named entity 'SOC' named entity 'adverse event' named entity 'ICU' named entity 'azithromycin' named entity 'Tocilizumab' named entity 'heparin' named entity 'alanine aminotransferase' named entity 'Standard Of Care' named entity 'pneumonia' named entity 'prophylactic' named entity 'Preliminary Results' named entity 'mortality rate' named entity 'IL-6' named entity 'CRP' named entity 'adverse effect' named entity 'INR' named entity 'secondary infection' named entity 'pharmacological effect' named entity 'steroid' named entity 'CRS' named entity 'CRS' named entity 'COVID-19' named entity 'IL-6 receptor' named entity 'March 14' named entity 'pneumonia' named entity 'Pneumonia' named entity 'alanine aminotransferase' named entity 'Linear Mixed Models' named entity 'American Thoracic Society' named entity 'inflammation' named entity 'clinical characteristics' named entity 'anti-inflammatory' named entity 'gaussian distribution' named entity 'COVID-19 disease' named entity 'hydroxychloroquine' named entity 'ICU' named entity 'Tocilizumab' named entity 'mortality rate' named entity 'INR' named entity 'CRS' named entity 'ICU' named entity 'CRP' named entity 'COVID' named entity 'standard of care' named entity 'laboratory tests' named entity 'SARS-CoV-2' named entity 'PCTI' named entity 'convalescent plasma' named entity 'missing data' named entity 'CRP' named entity 'SARS-CoV-2' named entity 'SOC' named entity 'infection' named entity 'neutrophils' named entity 'inflammatory conditions' named entity 'IL-6' named entity 'SOC' named entity 'COVID' named entity 'oxygen' named entity 'observational studies' named entity 'CRP' named entity 'platelets' named entity 'viral pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software